Thursday 21 November 2024

The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?

Pharmaceutical
4 July 2022
episode15-big

More on this story...

Pharmaceutical
The FDA and artificial intelligence
7 June 2021
Pharmaceutical
European drugmakers embrace artificial intelligence
3 December 2020
Pharmaceutical
Understanding the AI-enabled drug discovery landscape
8 July 2022
Pharmaceutical
Elix launches AI drug discovery platform
15 July 2022


More ones to watch >


Today's issue

HCW Biologics takes aim at CD8+ in deal with WY Biotech
Biotechnology
HCW Biologics takes aim at CD8+ in deal with WY Biotech
21 November 2024
Pharmaceutical
Leading Tac secures $14 million for IRAK4 degraders
21 November 2024
Biotechnology
Positive top-line data for NewAmsterdam’s obicetrapib and ezetimibe combo
21 November 2024
Biotechnology
Amgen names new president of research
21 November 2024
Biotechnology
Vyriad collaborates with Novartis on in vivo CAR-T cell therapies
21 November 2024
Biotechnology
EC approval for Pfizer’s Hympavzi
20 November 2024
Biotechnology
Flagship reveals new agreements under Pfizer link-up
20 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.




More Features in Pharmaceutical

Leading Tac secures $14 million for IRAK4 degraders
21 November 2024
Ascentage's lisaftoclax accepted for priority review in China
20 November 2024
Chris Boshoff takes on new role at Pfizer
20 November 2024
Cytokinetics and Bayer ink deal for aficamten in Japan
20 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze